Compounding complexity in drug manufacturing

As the demand for more complex molecules continues to rise, process development teams face the challenge of unlocking unattainable reactions, streamlining synthesis steps, and promoting sustainable manufacturing.

average number of steps required to synthesise a small molecule API in 2021

Almost doubled

number of steps required in last 20 years

>66%

increase in chiral centres in last 20 years

As your in silico partner

Basecamp Research expands your biocatalysis capabilities

Expand your toolbox

‍Unlock complex transformations by learn from nature

Access novel chemistries in rare enzyme classes

Secure novel IP without regulatory burden for Nagoya compliance

Process-ready enzymes

Computationally match enzymes to your process conditions

Validate and optimise substrate specificity before laboratory testing

Avoid labour-intensive evolution and high-throughput screening

Leapfrog engineering

Achieve a performant enzyme in weeks, not years

Align your R&D investment with your in-house strengths

Outsource efficiently at any stage, from cloning to scale-up

Make the most of your limited time and resources

From trial-and-error to in silico predictions

Enzyme engineering today

Our context-led discovery & design approach

Mine for starting points

Relies on sequence-based searches from public databases within known enzyme classes

Map the protein universe

No prior mechanistic insight required to leverage our map of enzymatic reactions — complete with genomic, chemical, and environmental context

Screen for hits

Depends on high-throughput in vitro testing to inform computational analysis

Match to your reaction

Prioritise the best enzymes for your desired reaction before lab testing, aided by our high-throughput, physics-based in silico validation

Evolve to improve

Requires labour-intensive rounds of directed evolution, and even more so to reach process conditions

Refine for scale-up

Enzymes designed to be process-ready from round 1, as our AI is informed by real-world contextual data

Beyond abundance

Superior starting points for enzyme design

Highly demanded biocatalysts

65x more
‍Imine reductases

26x more
‍Methyltranferases

25x more
‍Ketoreductases

Our superior abundance in diverse biocatalysts over UniProt and other public databases ensures the broadest possible pool to address even the most challenging substrates and reactions
‍
Through our biodiscovery process, we help our partners draw on vastly more natural starting points to design process-ready enzymes for your desired reaction conditions.

Partner with us to develop and license our novel enzymes.

Learn more

Partner with us

See how we can help with your target enzymes and applications

We partner with people all across the bioeconomy, including agritech, food, API manufacture, cosmetics & more.
‍
So whether you're a synthetic biologist developing living therapeutics, a metabolic engineer enhancing biofuel production, or an enzymologist designing biocatalysts for bioplastics, give us a shout!

Rooted in Access and Benefit Sharing

Future-proofed data collection

At the heart of our biodiscovery process is a our commitment to Access and Benefit Sharing (ABS). ABS is a cornerstone principle of the Convention on Biological Diversity and its Nagoya Protocol, which seeks to ensure fair and equitable sharing of benefits arising from the utilisation of genetic resources.

We're building a robust model for long term biodiversity protection through our global sampling partnerships. Each of our samples is collected in compliance with the Nagoya Protocol and with pre-negotiated permission to commercialise with our industry partners. Our aim is to create a world where industrial innovation protects, supports and revitalises our natural biodiversity.

Predictive biocatalysis for APIs